Should I buy Enovis (ENOV) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Enovis
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Canaccord Genuity | 17 % | -12.3 % | 6 | $45 +81% |
| Needham | 0 % | -26.0 % | 16 | $52 +109% |
✅ Reasons to believe
- 100% of analysts rate it a buy (Buy consensus, 5 ratings) — a sign of market conviction.
- Median price target $39, i.e. +57% from the current price ($25).
- The most reliable firm on ENOV, Canaccord Genuity (17% hit rate, 6 scored calls), targets $45 (call made on August 17, 2026, maturing on August 17, 2027) (+81%) in its most recent call, and $50 (call made on December 17, 2025, maturing on December 17, 2026) (+101%) in the one coming due soonest.
⚠️ Reasons to hesitate
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
- A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.
The analyst consensus on ENOV
Median target $39 (+57%) · 5 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Enovis now?
We won't decide for you. The facts: 100% of analysts rate it a buy, median target $39 (+57%), and Canaccord Genuity (most reliable on ENOV, 17%) targets $45. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Enovis?
Not according to analysts: the median target ($39) is still +57% above the current price ($25) (most reliable on ENOV: Canaccord Genuity, 17%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Enovis still worth investing in?
It depends on the gap between the price ($25) and its estimated value: analysts target $39 on median (+57%), with 100% buys (most reliable on ENOV: Canaccord Genuity, 17%). Cross-check with their real reliability on ENOV and the cautions above. Information, not advice.
What's the main risk in buying ENOV?
A 12-month target is not a guaranteed path: the price can fall in the meantime.
→ Go deeper: the full Enovis profile (consensus, analyst reliability, price target, performance).